Abstract
Background
Vascular smooth muscle cell (VSMC) proliferation following arterial injury plays a critical role in a variety of vascular proliferative disorders, including atherosclerosis and restenosis after balloon angioplasty. In this study, we tested the hypothesis that localized arterial infection at the time of balloon angioplasty with an adenovirus (ADV-tk) encoding the herpes simplex virus thymidine kinase gene (HSV-tk), followed by systemic ganciclovir administration, can inhibit VSMC proliferation and neointima formation in a well-characterized model of arterial injury and restenosis.
Materials and Methods
The left carotid arteries of 31 male Sprague-Dawley rats were subjected to balloon angioplasty and immediately infected with 2 × 109 pfu of either ADV-tk or a control adenovirus that does not encode a recombinant protein (ADV-ΔE1). Twenty-four hours after injury, animals from each experimental group were randomized to receive a course of systemic ganciclovir (ADV-tk/+GC, ADV-ΔE1/+GC) or saline (ADV-tk/-GC, ADV-ΔE1/-GC). VSMC DNA synthesis was measured by 5’-bromode-oxyuridine (BrdU) incorporation 2–4 days after balloon injury. The extent of restenosis, expressed as the neointima to media (I/M) area ratio was determined by digital planimetry 20 days after balloon injury in each of the four treatment groups. Immunohistochemistry using a mAb to von Willebrand factor (vWF) was used to determine the effects of ADV-tk infection and ganciclovir treatment on re-endothelialization of the carotid arteries 20 days following balloon angioplasty.
Results
Forty-one percent of the medial VSMCs in the ADV-tk/-GC arteries were labeled with BrdU 4 days after balloon injury. In contrast, ADV-tk infected animals that were treated with systemic ganciclovir (ADV-tk/+GC) displayed a 40% reduction in BrdU-staining medial VSMCs (p < 0.03). I/M area ratios of the three control groups were 1.17 ± 0.18 (ADV-tk/-GC, n = 5), 1.15 ± 0.10 (ADV-ΔE1/+GC, n = 6), and 0.91 ± 0.08 (ADV-ΔE1/-GC, n = 6). These differences were not statistically significant (p > 0.05). In contrast, the ADV-tk/+GC animals (n = 6) displayed an I/M area ratio of 0.49 ±0.13 which was significantly lower than that seen in each of the three control groups (p < 0.02). None of the treated animals showed evidence of significant organ toxicity at autopsy. A regenerated endothelium was observed in the ADV-tk/ +GC animals 20 days after balloon injury.
Conclusions
Localized arterial infection with ADV-tk at the time of balloon angioplasty followed by systemic ganciclovir therapy reduces VSMC proliferation and neointimal expansion in the rat carotid artery injury model. Moreover, combined treatment with ADV-tk and systemic ganciclovir does not result in systemic toxicity and appears to selectively eliminate proliferating VSMCs, while preserving the capacity of the injured arterial segments to re-endothelialize within 3 weeks of injury. Taken together, these results support the feasibility of using this gene therapy approach for the treatment of human vascular proliferative disorders.
Similar content being viewed by others
References
Ross R. (1993) The pathogenesis of atherosclerosis: A perspective for the 1990’s. Nature 362: 801–809.
Forrester JS, Fishbein M, Helfant R, Fagin J. (1991) A paradigm for restenos is based on cell biology: Clues for the development of new preventive therapies. J. Am. Coll. Cardiol. 17: 758–769.
Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. (1990) Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferation. J. Am. Coll. Cardiol. 15: 1667–1687.
Schwartz RS, Holmes DR, Topol EJ. (1992) The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J. Am. Coll. Cardiol. 20: 1284–1293.
Liu MW, Roubin GS, King SB. (1989) Restenosis after coronary angioplasty. Potential biologic determinants and role of intimai hyperplasia. Circulation 79: 1374–1387.
Borrelli E, Heyman R, Hsi M, Evans RM. (1988) Targeting of an inducible toxic phenotype in animal cells. Proc. Natl. Acad. Sci. U.S.A. 85: 7572–7562.
Heyman RA, Borrelli E, Lesley J, et al. (1989) Thymidine kinase obliteration: Creation of transgenic mice with controlled immune deficiency. Proc. Natl. Acad. Sci. U.S.A. 86: 2698–2702.
Culver KW, Van Gilder J, Link CJ, et al. (1994) Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum. Gene. Ther. 5: 343–379.
Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550–1552.
Breakefield XO, DeLuca NA. (1991) Herpes simplex virus for gene delivery to neurons. New Biol. 3: 203–218.
Moolten FL, Wells JM, Heyman RA, Evans RM. (1990) Lymphoma regression induced by ganciclovir in mice beraring a herpes thymidine kinase transgene. Hum. Gene. Ther. 1: 125–134.
Moolten FL, Wells JM. (1990) Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 82: 297–300.
Plautz G, Nabel EG, Nabel GJ. (1991) Selective elimination of recombinant genes in vivo with a suicide retroviral vector. New Biol. 3: 709–715.
Chang MW, Barr E, Seltzer J, et al. (in press) Cytostatic gene therapy for vascular proliferative disorders using a constitutively active form of Rb. Science.
Ohno T, Gordon D, San H, et al. (1994) Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 265: 781–784.
Guzman RJ, Lemarchand P, Crystal RG, Epstein SE and Finkel T. (1993) Efficient and selective adenovirus-mediated gene transfer into vascular neointima. Circulation 88: 2838–2848.
Barr E, Carroll J, Kalynych AM, et al. (1994) Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus. Gene. Ther. 1: 51–58.
Clowes AW, Reidy MA, Clowes MM. (1983) Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab. Invest. 49: 327–333.
Lindner V, Olson NE, Clowes AW, Reidy MA. (1992) Inhibition of smooth muscle cell proliferation in injured rat arteries. J. Clin. Invest. 90: 2044–2049.
Morishita R, Gibbons GH, Ellison KE, et al. (1993) Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. U.S.A. 90: 8474–8478.
Nabel EG, Shum L, Pompili VJ, et al. (1993) Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc. Natl. Acad. Sci. U.S.A. 90: 10759–10763.
Baumgartner HR, Muggli R, Tschopp TB, Turitto VT. (1976) Platelet adhesion, release and aggregation in flowing blood: Effects of surface properties and platelet function. Throm. Haem. 35: 124–138.
Moncada S, Herman AG, Higgs EA, Vane JR. (1977) Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Throm. Res. 11: 323–344.
Furchgott RF. (1983) Role of endothelium in responses of vascular smooth muscle. Circ. Res. 53: 557–573.
Furchgott RF, Zawadzki JV. (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373–376.
Shimokawa H, Vanhoutte PM. (1989) Impaired endothelium-dependent relaxation to aggregating platelets and related vasoactive substances in porcine coronary arteries in hypercholesterolemia and atherosclerosis. Circ. Res. 64: 900–914.
Lemarchand P, Jones M, Yamada I, et al. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ. Res. 72: 1132–1138.
Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P. (1992) Widespread long-term gene transfer to mouse skeletal muscles and heart. J. Clin. Invest. 90: 626–630.
Eisler A, Falck-Pedersen E, Alvira M, et al. (1993) Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 90: 11498–11502.
Engelhardt JF. (1993) Adenovirus-mediated transfer of the CFTR gene to lung of non-human primates: Biological efficacy study. Hum. Gene. Ther. 4: 759–769.
Zabner J, et al. (1994) Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nature Gen. 6: 75–83.
Tripathy SK, Goldwasser E, Barr E, Leiden JM. (in press) Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus. Proc. Natl. Acad. Sci. U.S.A.
Thornton MA, Gruntzig AR, Hollman J, King SB, Gouglas JS. (1984) Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: A randomized trial. Circulation 69: 721–727.
MERCATOR Study Group. (1992) Does the new angiotensin converting enzyme inhibitor Cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: A multicenter, randomized double-blind placebo controlled trial. Circulation 86: 100–110.
Ellis SG, Roubin GS, Wilentz J, Douglas JS, King SB. (1989) Effect of 18–24 hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am. Heart J. 117: 777–782.
Landau C, Lange RA, Hillis LD. (1994) Percutaneous transluminal coronary angioplasty. N. Engl. Jour. Med. 330: 981–993.
Muller DW, Ellis SG, Topol EJ. (1991) Colchicine and antineoplastic therapy for the prevention of restenosis after percutaneous coronary interventions. J. Am. Coll. Cardiol. 17(Suppl B): 126B–131B.
Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD. (1992) Antisense c-myb oligonucleotides inhibit intimai arterial smooth muscle cell accumulation in vivo. Nature 359: 67–70.
Barr E, Leiden JM. (1994) Somatic gene therapy for cardiovascular disease. Trends Card. Med. 4: 57–63.
Leiden JM, Barr E. (1994) In vivo gene transfer into the heart. In: Wolff JA (ed). Gene Therapeutics: Methods and Applications of Direct Gene Transfer. Birkhauser, Boston.
Chang MW, Leiden JM. (in press) Gene and cell-based therapies for myocardial dysfunction. In: Edelman ER (ed). Molecular Interventions and Local Drug Delivery in Cardiovascular Disease. W. B. Saunders, London.
Channock R, Ludwig W, Huebner RJ, et al. (1966) Immunization by selective infection with type 4 adenovirus grown in human diploid tissue cultures. I. Safety and lack of oncogenicity and tests for potency in volunteers. J.A.M.A. 195: 445–452.
Horwitz MS. (1990) The adenoviruses. In: Fields BN, Knipe DM (eds). Virology. Raven Press, New York.
Yang Y, Nunes FA, Berencsi K, et al. (1994) Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 91: 4407–4411.
Yang Y, Ertl HCJ, Wilson JM. (1994) MHC class-I restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with El-deleted recombinant adenoviruses. Immunity 1: 433–442.
Powell JS, Clozel J-P, Muller RKM, et al. (1989) Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245: 186–188.
Volker W, Faber V. (1990) Aspirin reduces the growth of medial and neointimal thickenings in balloon-injured rat carotid arteries. Stroke 21(Suppl 4): IV44–IV45.
Acknowledgments
The authors would like to thank Lingling Xu and Hong San, MD, for their technical assistance. This work was supported in part by a grant from Vical Inc., La Jolla, CA.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chang, M.W., Ohno, T., Gordon, D. et al. Adenovirus-Mediated Transfer of the Herpes Simplex Virus Thymidine Kinase Gene Inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation Following Balloon Angioplasty of the Rat Carotid Artery. Mol Med 1, 172–181 (1995). https://doi.org/10.1007/BF03401565
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03401565